Orally administered cannabidiol (CBD) does not produce false-positive tests for THC on the Securetec DrugWipe® 5S or Dräger Drug Test® 5000

View/ Open
File version
Accepted Manuscript (AM)
Author(s)
McCartney, Danielle
Kevin, Richard C
Suraev, Anastasia S
Irwin, Christopher
Grunstein, Ronald R
Hoyos, Camilla M
McGregor, Iain S
Griffith University Author(s)
Year published
2021
Metadata
Show full item recordAbstract
Many jurisdictions use point-of-collection (POC) oral fluid testing devices to identify driving under the influence of cannabis, indexed by the presence of Δ9 -tetrahydrocannabinol (THC), an intoxicating cannabinoid, in oral fluid. While use of the non-intoxicating cannabinoid, cannabidiol (CBD), is not prohibited among drivers, it is unclear whether these devices can reliably distinguish between CBD and THC, which have similar chemical structures. This study determined whether orally administered CBD produces false-positive tests for THC on standard, POC oral fluid testing devices. In a randomised, double-blind, crossover ...
View more >Many jurisdictions use point-of-collection (POC) oral fluid testing devices to identify driving under the influence of cannabis, indexed by the presence of Δ9 -tetrahydrocannabinol (THC), an intoxicating cannabinoid, in oral fluid. While use of the non-intoxicating cannabinoid, cannabidiol (CBD), is not prohibited among drivers, it is unclear whether these devices can reliably distinguish between CBD and THC, which have similar chemical structures. This study determined whether orally administered CBD produces false-positive tests for THC on standard, POC oral fluid testing devices. In a randomised, double-blind, crossover design, healthy participants (n=17) completed four treatment sessions involving the administration of either placebo, or 15, 300, or 1500mg pure CBD in a high fat dietary supplement. Oral fluid was sampled, and the DrugWipe®-5S (DW-5S; 10ng·mL-1 THC cut-off) and Drug Test® 5000 (DT5000; 10ng·mL-1 THC cut-off) devices administered, at Baseline (pre-treatment) and ~20-, ~145- and ~185-minutes post-treatment. Oral fluid cannabinoid concentrations were measured using ultra-high performance liquid chromatography-tandem mass spectrometry. Median (IQR) oral fluid CBD concentrations were highest at ~20-minutes, quantified as 0.4 (6.0), 15.8 (41.6) and 167 (233) ng·mL-1 on the 15, 300 and 1500mg CBD treatments, respectively. THC, cannabinol and cannabigerol were not detected in any samples. 259 DW-5S and 256 DT5000 tests were successfully completed, and no THC-positive tests were observed. Orally administered CBD does not appear to produce false-positive (or true-positive) tests for THC on the DW-5S and DT5000. The likelihood of an individual who is using a CBD (only) oral formulation being falsely accused of DUIC therefore appears low.
View less >
View more >Many jurisdictions use point-of-collection (POC) oral fluid testing devices to identify driving under the influence of cannabis, indexed by the presence of Δ9 -tetrahydrocannabinol (THC), an intoxicating cannabinoid, in oral fluid. While use of the non-intoxicating cannabinoid, cannabidiol (CBD), is not prohibited among drivers, it is unclear whether these devices can reliably distinguish between CBD and THC, which have similar chemical structures. This study determined whether orally administered CBD produces false-positive tests for THC on standard, POC oral fluid testing devices. In a randomised, double-blind, crossover design, healthy participants (n=17) completed four treatment sessions involving the administration of either placebo, or 15, 300, or 1500mg pure CBD in a high fat dietary supplement. Oral fluid was sampled, and the DrugWipe®-5S (DW-5S; 10ng·mL-1 THC cut-off) and Drug Test® 5000 (DT5000; 10ng·mL-1 THC cut-off) devices administered, at Baseline (pre-treatment) and ~20-, ~145- and ~185-minutes post-treatment. Oral fluid cannabinoid concentrations were measured using ultra-high performance liquid chromatography-tandem mass spectrometry. Median (IQR) oral fluid CBD concentrations were highest at ~20-minutes, quantified as 0.4 (6.0), 15.8 (41.6) and 167 (233) ng·mL-1 on the 15, 300 and 1500mg CBD treatments, respectively. THC, cannabinol and cannabigerol were not detected in any samples. 259 DW-5S and 256 DT5000 tests were successfully completed, and no THC-positive tests were observed. Orally administered CBD does not appear to produce false-positive (or true-positive) tests for THC on the DW-5S and DT5000. The likelihood of an individual who is using a CBD (only) oral formulation being falsely accused of DUIC therefore appears low.
View less >
Journal Title
Drug Testing and Analysis
Copyright Statement
© 2021 John Wiley & Sons, Ltd. This is the peer reviewed version of the following article: Orally administered cannabidiol (CBD) does not produce false-positive tests for THC on the Securetec DrugWipe® 5S or Dräger Drug Test® 5000, Drug Testing and Analysis, 2021, which has been published in final form at https://doi.org/10.1002/dta.3153. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
Subject
Analytical chemistry
Biochemistry and cell biology
cannabidiol
cannabis
drug driving
oral fluid
point-of-collection testing